Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy - Scorecard - MDSpire

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

  • By

  • Yao Qiu

  • Xincai Zhao

  • Juan Chen

  • Manman Zhang

  • Yonggang Wang

  • Cheng Guo

  • Jianping Zhang

  • Rong Xu

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Analysis of Immune-Related Adverse Events and Their Risk Factors in Cancer Patients Undergoing Combination Therapy with Immune Checkpoint Inhibitors

At a Glance

CategoryDetail
Condition
Key MechanismsReactivated cellular immunity affecting various organ systems, with emphasis on the potential for severe complications.
Target Population
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • p
      • a
      • r
      • a
      • m
      • e
      • t
      • e
      • r
      • s
      • f
      • o
      • r
      • r
      • i
      • s
      • k
      • -
      • s
      • t
      • r
      • a
      • t
      • i
      • f
      • i
      • e
      • d
      • m
      • o
      • n
      • i
      • t
      • o
      • r
      • i
      • n
      • g
      • .

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • management

        Related Resources & Content

        Original Source(s)

        Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

        • by Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu

        • May 29, 2026

        Related Content

        MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

        Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

        Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2